...
首页> 外文期刊>RSC Advances >In vitro combinations of inert phenolato Ti(IV) complexes with clinically employed anticancer chemotherapy: synergy with oxaliplatin on colon cells
【24h】

In vitro combinations of inert phenolato Ti(IV) complexes with clinically employed anticancer chemotherapy: synergy with oxaliplatin on colon cells

机译:在临床上使用抗癌化疗的惰性苯酚Ti(IV)复合物的体外组合:在结肠细胞上与Oxaliplatin的协同作用

获取原文
获取原文并翻译 | 示例

摘要

Advanced anticancer phenolato titanium(IV) complexes were combined with known chemotherapeutic anticancer drugs applied in the clinic and were analyzed in vitro on cell lines most sensitive to the Ti(IV) complex and relevant to the clinical application of the known drugs. Combination of the Ti(IV) complex with cisplatin on ovarian cells showed mostly an additive behavior, also on a line resistant to cisplatin. Combination of the Ti(IV) complex with fluorouracil on colon cells gave near additive behavior, and that with oxaliplatin gave a synergistic behavior at a wide range of Ti : Pt ratios, but only when the drugs were administered together. Increasing the time intervals between the administration of Ti and of Pt turned the behavior to antagonistic, suggesting some deactivation of Pt by the Ti agent. For combinations where the drugs were applied together, the behavior depended on the effect level, and higher effects gave greater synergism, implying that technical aspects such as solubility are influential. Nevertheless, more complex patterns recorded for combinations where the drugs had been applied separately suggested multiple mechanisms with different concentration dependence. Overall the results point to high medicinal potential for the tested compounds for anticancer combination treatments.
机译:先进的抗癌苯钛(IV)配合物与临床中的已知化学治疗抗癌药物合并,并在对Ti(IV)复合物最敏感的细胞系上进行体外分析,并与已知药物的临床应用相关。 Ti(IV)复合物与顺铂对卵巢细胞的组合主要是一种添加剂行为,也存在于对顺铂的抗性线。 Ti(iv)复合物与氟尿嘧啶对结肠细胞的组合给出了附近的添加剂行为,并且随着oxaliplatin在宽范围的Ti:Pt比率下产生协同行为,但仅当药物一起施用时。增加Ti和Pt施用之间的时间间隔转动对拮抗的行为,表明TI代理的一些停用PT。对于将药物施加在一起的组合中,依赖于效果水平的行为,较高的效果产生了更大的协同作用,这意味着诸如溶解度的技术方面是有影响力的。然而,记录了更多复杂的模式,用于分别应用药物的组合,提出了不同浓度依赖的多种机制。总体而言,结果指出了测试化合物的抗癌组合治疗的高药用潜力。

著录项

  • 来源
    《RSC Advances 》 |2018年第11期| 共6页
  • 作者

    Ganot N.; Tshuva E. Y.;

  • 作者单位

    Hebrew Univ Jerusalem Inst Chem IL-9190401 Jerusalem Israel;

    Hebrew Univ Jerusalem Inst Chem IL-9190401 Jerusalem Israel;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号